Tag: biotechnology
-
Small Biz Grant Funds Non-Viral Gene Editing Delivery
National Institutes of Health is financing a delivery method for gene-editing therapies to blood-forming stem cells with natural lipid bubbles instead of viruses.
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Trial Okayed for Engineered Cell Cancer Therapy
A clinical trial is set to begin testing engineered immune-system cells designed to precisely target and infiltrate cancerous tumors without other potentially toxic proteins.
-
Trial Shows Oral Covid-19 Vaccine Produces Antibodies
A clinical trial shows a Covid-19 vaccine taken as a tablet produces protective antibodies in nasal membranes that in some cases last for up to a year.
-
Synthetic Bio Microbiome Biotech Gains $15M in Seed Funds
A developer of therapies produced with synthetic biology for diseases linked to microbes in the gut is raising $15 million in seed financing.
-
Infographic – US Biotech Investments Stay Strong
The first half half of 2022 shows venture investments in U.S. biotechnology start-ups cooled from the blistering pace of last year, but biotech remains a robust sector.
-
NIH Funding Engineered Phage Screening Device
National Institutes of Health is funding initial development of a microfluidic device that tests engineered viruses for their ability to kill disease-causing bacteria.
-
Precision Protein Design Start-Up Gains $40M in Early Funds
A start-up company designing and testing precise proteins within live animals to speed creation of new therapeutics is raising $40 million in its first venture round.
-
Biotechs Explore Gut-Brain Axis for Mental Health
Two biotechnology companies are advancing basic research findings connecting gut microbes with the brain to develop new therapies for neurological disorders.
-
Trial Begins of Precise Gene Editing for Heart Disease
A clinical trial is underway evaluating a precise form of Crispr gene editing as a one-time therapy for an inherited form of heart disease.